The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act ---- Beginning January 1, 2025, providers can ...

Exparel (bupivacaine liposome injectable suspension), to facilitate better insurance coverage for the drug. This new J-code will take effect on Jan. 1, 2025, replacing the existing C-code (C9290 ...

The Food and Drug Administraton has approved Jiangsu Hengrui Pharma's application for bupivacaine liposome, which is a generic of Pacira BioScience's non-opioid pain drug Exparel. Hengrui is the ...

Bupivacaine HCl 2.5mg/mL, 5mg/mL; epinephrine 1:200000; soln for inj. Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical ...

Through his work as a clinical fellow in paediatric surgery at the University Hospital Southampton NHS Foundation Trust, he ...

Droperidol was a first-line, highly effective agent for the treatment of PONV for over 30 years. It has the most postmarketing surveillance data of any of the currently used antiemetic agents.

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

Intradermal testing with lidocaine 1%, mepivacaine 2%, and bupivacaine 0.5% was performed on 8 patients; 3 had positive reactions to lidocaine, and 1 had a positive reaction to mepivacaine.

Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all ...